The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor
PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.20, sa.5, ss.373-379, 2003 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 20 Sayı: 5
- Basım Tarihi: 2003
- Doi Numarası: 10.1080/08880010390203954
- Dergi Adı: PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.373-379
- Anahtar Kelimeler: acute myeloblastic leukemia, children, high-dose methylprednisolone, myeloid tumor, ACUTE LYMPHOBLASTIC-LEUKEMIA, PEDIATRIC-ONCOLOGY-GROUP, MYELODYSPLASTIC SYNDROME, GRANULOCYTIC SARCOMA, DIFFERENTIATION, CELLS, REMISSION, EXPRESSION, INDUCTION, SENSITIVITY
- Gazi Üniversitesi Adresli: Evet
Özet
The authors have previously demonstrated a favorable effect of high-dose methylprednisolone (HDMP), which can induce differentiation and apoptosis of leukemic cells in children with acute myeloblastic leukemia (AML). Here, they evaluate the effect of short-course HDMP in 2 children with acute myeloblastic leukemia (AML-M2) presented with myeloid tumor (MT). Methylprednisolone (20 or 30 mg/kg/day) was given orally, in a single dose, without using other antileukemic agents. Rapid cytoreduction in MT, peripheral blood, and bone marrow blasts was observed in both children following short-course (4 or 7 days) HDMP treatment, possibly due to HDMP-induced differentiation and apoptosis of leukemic cells. The effects of HDMP should be explored in patients with other subtypes of AML who present with MT.